Medidata Solutions, Inc. (NASDAQ:MDSO) had its price objective reduced by Wells Fargo & Company from $83.00 to $80.00 in a research report report published on Friday, October 27th. They currently have a market perform rating on the stock.
A number of other analysts have also weighed in on MDSO. J P Morgan Chase & Co upped their price target on shares of Medidata Solutions to $87.00 and gave the stock an overweight rating in a research note on Tuesday, July 18th. Citigroup Inc. reissued a buy rating and set a $94.00 target price (up from $77.00) on shares of Medidata Solutions in a research note on Monday, July 10th. KeyCorp reissued a buy rating and set a $86.00 target price on shares of Medidata Solutions in a research note on Sunday, September 17th. Royal Bank Of Canada began coverage on shares of Medidata Solutions in a report on Tuesday, September 19th. They set a sector perform rating and a $82.00 price target on the stock. Finally, Morgan Stanley boosted their price target on shares of Medidata Solutions from $74.00 to $86.00 and gave the company an overweight rating in a report on Thursday, July 20th. Five research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Medidata Solutions has an average rating of Buy and a consensus target price of $84.25.
Shares of Medidata Solutions (MDSO) traded up $0.73 during mid-day trading on Friday, reaching $65.69. 516,200 shares of the company’s stock were exchanged, compared to its average volume of 548,634. The firm has a market cap of $3,840.30, a price-to-earnings ratio of 79.14, a P/E/G ratio of 3.95 and a beta of 1.78. Medidata Solutions has a 52-week low of $47.77 and a 52-week high of $85.92. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.29 and a quick ratio of 3.37.
Medidata Solutions (NASDAQ:MDSO) last released its earnings results on Thursday, October 26th. The company reported $0.33 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.31 by $0.02. Medidata Solutions had a net margin of 7.84% and a return on equity of 11.54%. The company had revenue of $140.08 million during the quarter, compared to the consensus estimate of $141.27 million. During the same quarter in the previous year, the firm earned $0.28 EPS. The company’s revenue was up 16.7% on a year-over-year basis. research analysts predict that Medidata Solutions will post 0.77 EPS for the current fiscal year.
In related news, COO Michael L. Capone sold 5,000 shares of Medidata Solutions stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $74.53, for a total transaction of $372,650.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Tarek Sherif sold 200,000 shares of Medidata Solutions stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $68.76, for a total transaction of $13,752,000.00. The disclosure for this sale can be found here. Insiders sold a total of 220,000 shares of company stock valued at $15,190,400 in the last 90 days. Corporate insiders own 5.80% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of MDSO. Dimensional Fund Advisors LP increased its holdings in Medidata Solutions by 40.9% during the third quarter. Dimensional Fund Advisors LP now owns 93,853 shares of the company’s stock worth $7,327,000 after buying an additional 27,264 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its position in Medidata Solutions by 38.3% during the third quarter. Schwab Charles Investment Management Inc. now owns 326,950 shares of the company’s stock worth $25,522,000 after purchasing an additional 90,572 shares during the period. Wells Fargo & Company MN lifted its position in Medidata Solutions by 4.1% during the third quarter. Wells Fargo & Company MN now owns 219,054 shares of the company’s stock worth $17,099,000 after purchasing an additional 8,658 shares during the period. Axiom International Investors LLC DE lifted its position in Medidata Solutions by 16.2% during the third quarter. Axiom International Investors LLC DE now owns 99,506 shares of the company’s stock worth $7,767,000 after purchasing an additional 13,886 shares during the period. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in Medidata Solutions by 11.0% during the third quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 8,534 shares of the company’s stock worth $666,000 after purchasing an additional 847 shares during the period. Institutional investors own 97.52% of the company’s stock.
About Medidata Solutions
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.